Lupin Divests US Women's Health Specialty Business to Evofem Biosciences

Lupin has sold its women's health specialty business in the US to Evofem Biosciences Inc. The deal could be worth up to USD 84 million, depending on future milestones. This business focuses on Solosec, an FDA-approved single-dose antimicrobial agent for bacterial vaginosis (BV) and trichomoniasis.

Representative image

Fabrice Egros, Lupin's President of Global Corporate Development, stated, "This divestment is another step in aligning our US specialty business with our strategic plan to build our specialty business in therapeutic areas where we have building blocks of synergy. These include respiratory and neurological diseases."

Focus on Solosec

The US Commercial Women's Health Specialty Business of Lupin was primarily engaged in the commercialisation of Solosec secnidazole 2g oral granules. Solosec provides a complete course of therapy for treating BV and trichomoniasis, two prevalent sexual health infections.

Under the terms of the agreement, Lupin stands to gain up to USD 84 million based on future contingent milestones. This potential total consideration underscores the value placed on the women's health specialty business by Evofem Biosciences.

Strategic Alignment

Egros highlighted that this divestment aligns with Lupin's broader strategy to focus on therapeutic areas where they have established synergies. The company aims to strengthen its presence in respiratory and neurological diseases through this strategic move.

Evofem CEO Saundra Pelletier commented on the acquisition, saying, "The acquisition of the business aligns and advances the company's mission to improve access to innovative and differentiated options that impact women's daily lives."

Leveraging Infrastructure

Pelletier further added, "We can now fully leverage our commercial infrastructure, maximise our strong physician relationships, and re-launch an asset with tremendous growth potential." This statement reflects Evofem's confidence in their ability to enhance the commercial success of Solosec.

The transaction is seen as a win-win for both companies. Lupin can now concentrate on its core areas of expertise while Evofem gains a valuable asset that fits well within its existing portfolio.

On Monday, shares of Lupin closed 1.95% higher at Rs 1,832.10 each on the BSE. This positive market reaction indicates investor confidence in Lupin's strategic direction following the divestment.

This deal marks a significant step for both companies as they continue to refine their strategic focuses and leverage their strengths in specialised therapeutic areas.